Inhibiting the heat shock factor 1-regulated transcriptional program in cancer

抑制癌症中热休克因子 1 调节的转录程序

• 批准号: 8829197
• 负责人: JOHN A PORCO
• 金额: $ 53.2万
• 依托单位: WHITEHEAD INSTITUTE FOR BIOMEDICAL RES
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-16 至 2017-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8829197
• 关键词: Address; Animals; Antineoplastic Agents; Biocompatible Materials; Biological Assay; Biological Factors; Cell Culture Techniques; Cell Proliferation; Cells; Chemicals; Clinical Research; Collaborations; DNA Sequence Alteration; Development; Drug Kinetics; Drug effect disorder; Ensure; Future; Genetic; Goals; Grant; Health; Heat-Shock Response; Hot Spot; Human; In Vitro; Joints; Knock-out; Lead; Lesion; Libraries; Malignant - descriptor; Malignant Neoplasms; Methodology; Monitor; Mus; Mutation; Natural Resources; Oncogenic; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacodynamics; Principal Investigator; Process; Property; Protein p53; Reporter; Research Personnel; Resistance; Resources; Societies; Specificity; Structure-Activity Relationship; System; Testing; Therapeutic Index; Transgenic Mice; United States National Institutes of Health; Validation; Wild Type Mouse; Work; analog; anticancer activity; biological adaptation to stress; cancer initiation; coping; design; drug development; drug metabolism; heat-shock factor 1; high throughput screening; improved; in vivo; inhibitor/antagonist; mouse model; neoplastic cell; professor; programs; research clinical testing; response; rocaglamide; scaffold; small molecule; tumor initiation; tumor progression; tumor xenograft

DESCRIPTION (provided by applicant): In previous work we have demonstrated that Heat Shock Factor 1 (HSF1), master regulator of the mammalian heat shock response acts in a powerful, multi-faceted manner to enable malignant transformation both in cell culture and in transgenic mice. When compared to Hsf1 wild type mice, transgenic mice in which Hsf1 is knocked out are dramatically resistant to the formation of cancers driven by a variety of oncogenic lesions including activating mutations of RAS and hot-spot mutations of the tumor suppressor p53. In addition to highlighting the antitumor activity of targeting HSF1, the ability o mice to tolerate complete genetic knockout of HSF1 suggests that a useful therapeutic index is likely to exist for selective inhibitors of HSF1. Unfortunately, no such small molecules are currently known. Therefore, the goal of this project is to develop drug-like inhibitors of the HSF1 regulated transcriptional program with potent and selective activity in mice. We hypothesize that such inhibitors will be invaluable in probing how this ancient, highly conserved stress response makes it possible for cells to cope with the problems imposed by malignancy. They will also serve as promising leads for the future development of useful anticancer drugs with a completely new mode of action. Supported by a previous R-03 grant to one of the principal investigators on this project, we recently completed a >300,000 compound high throughput screen (HTS) through the NIH MLPCN program designed to identify selective inhibitors of HSF1. One of our most promising hits was the natural product rocaglamide A (RocA). To move from screen hit to a probe with potent and selective activity in animals, a medicinal chemistry collaboration has been established with another investigator who leads a nearby Chemical Methodology and Library Development (CMLD-BU) center. His group has achieved directed synthesis of diverse structural analogs of RocA starting from simple materials. Our joint expertise and resources ensure an adequate supply of material for biological studies independent of limited natural resources and have allowed us to pursue initial structure activity relationship (SAR) studies. These have identified compounds with more potent anticancer activity, but significant target-specificity issues and pharmacological liabilities remain to be addressed. In direct response to the mandate of PAR-12-060, we propose to undertake "iterative bioassay and chemical optimization cycles" to transition a validated HTS hit to a useful in vivo chemical probe.

描述（由申请人提供）：在以前的工作中，我们已经证明了热休克因子1（HSF 1），哺乳动物热休克反应的主要调节因子，以强大的、多方面的方式起作用，从而使细胞培养物和转基因小鼠中的恶性转化成为可能。当与Hsf 1野生型小鼠相比时，敲除Hsf 1的转基因小鼠对由多种致癌病变驱动的癌症形成具有显著抗性，所述致癌病变包括RAS的激活突变和肿瘤抑制因子p53的热点突变。除了突出靶向HSF 1的抗肿瘤活性之外，小鼠耐受HSF 1的完全基因敲除的能力表明，HSF 1的选择性抑制剂可能存在有用的治疗指数。不幸的是，目前还没有这样的小分子。因此，本项目的目标是开发HSF 1的药物样抑制剂 在小鼠中具有有效和选择性活性的受调控的转录程序。我们假设，这种抑制剂将是非常宝贵的探索如何古老的，高度保守的应激反应，使细胞有可能科普恶性肿瘤所带来的问题。它们也将作为未来开发具有全新作用模式的有用抗癌药物的有希望的先导。在之前的R-03资助的支持下，我们最近通过NIH MLPCN计划完成了一项超过300，000个化合物的高通量筛选（HTS），该计划旨在识别HSF 1的选择性抑制剂。我们最有希望的成功之一是天然产品罗格列酰胺A（RocA）。为了从屏幕点击转移到在动物中具有有效和选择性活性的探针，与另一位领导附近化学方法和库开发（CMLD-BU）中心的研究人员建立了药物化学合作。他的团队已经从简单的材料开始实现了RocA的多种结构类似物的定向合成。我们的共同专业知识和资源确保了生物学研究的材料供应充足，独立于有限的自然资源，并使我们能够进行初步的结构活性关系（SAR）研究。这些已经确定了具有更有效的抗癌活性的化合物，但重要的靶向特异性问题和药理学责任仍有待解决。作为对PAR-12-060指令的直接响应，我们建议进行“迭代生物测定和化学优化循环”，将经验证的HTS命中转换为有用的 体内化学探针。